Bausch, Teva face lawsuit for delay in generic version of Xifaxan

1 day ago 2

• Healthcare

• Comments

Love Employee/iStock via Getty Images

Bausch Health (NYSE:BHC) and Teva (NYSE:TEVA) are facing a lawsuit accusing them of conspiring to delay the release of a cheaper generic version of Bausch’s diarrhea drug, Xifaxan, keeping prices artificially high, according to a Reuters article.

The case, filed in

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Bausch, Teva face lawsuit for delay in generic version of Xifaxan